Atlas FDA

Ventana PD-L1 (SP263)

FDA premarket approval P160046/S004 · decided 2018-06-01

Approval details

PMA number
P160046
Supplement
S004
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
Ventana PD-L1 (SP263)
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Applicant
Ventana Medical Systems, Inc.
Date received
2018-04-03
Decision date
2018-06-01
Days to decision
59 days
Decision code
APPR
Product code
PLS
Advisory committee
Pathology
Expedited review
No
Location
Tucson, AZ
Statement
Approval for additional analytical validation data and associated updated product labeling.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Roche Digital Pathology Dx (K242783)Ventana Medical Systems, Inc.2024-12-17
VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail (08507023001) (DEN240025)Ventana Medical Systems, Inc.2024-12-05
Roche Digital Pathology Dx (VENTANA DP 200) (K232879)Ventana Medical Systems, Inc.2024-06-14
CINtec Histology (K212176)Ventana Medical Systems, Inc.2021-12-10
VENTANA CD30 (Ber-H2) RxDx Assay (K172471)Ventana Medical Systems, Inc.2018-05-08
CINtec Histology (50 tests), CINtec Histology (250 tests) (DEN160019)Ventana Medical Systems, Inc.2017-03-04
Virtuoso System for IHC PR (1E2) using iScan HT (K142965)Ventana Medical Systems, Inc.2015-07-16
VIRTUOSO SYSTEM FOR IHC ER (SP1) WITH BENCHMARK ULTRA STAINER (K140465)Ventana Medical Systems, Inc.2014-03-20